In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BeyondSpring Inc.

www.beyondspringpharma.com

Latest From BeyondSpring Inc.

BeyondSpring’s Pivotal NSCLC Trial For Plinabulin Designed To Avoid Bavencio’s JAVELIN 200 Failure

Lessons learned about blinding and stratification from Pfizer and Merck KGaA’s earlier Phase III disappointment shaped the design of BeyondSpring's ongoing Phase III trial of plinabulin in second- and third-line non-small cell lung cancer.

Clinical Trials Cancer

Finance Watch: Genmab Launches This Year's Biggest Biopharma IPO In The US

Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.

Business Strategies Financing

Choose Carefully For China Drug Development Success: White Paper

By avoiding crowded space and focusing instead on therapeutic areas with large potential, China remains attractive for drug developers, notes a recent white paper from investment bank China E-Capital.

China Commercial

BeyondSpring CEO On Plinabulin's Dual Regulatory Pathway For US and China

BeyondSpring’s lead clinical asset, plinabulin, is currently in late-stage global registrational studies for the prevention of chemotherapy-induced neutropenia and treatment of lung cancer, with read-outs expected soon.  CEO Lan Huang discussed coming catalysts and their potential with Scrip.

Commercial Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BeyondSpring Inc.
  • Senior Management
  • Lan Huang, PhD, CEO
    Edward Dongheng Liu, CFO
    Ramon Mohanlal, MD, PhD, EVP, R&D & CMO
    G. Kenneth Lloyd, PhD, CSO
    Richard J Daly, COO
  • Contact Info
  • BeyondSpring Inc.
    Phone: (646) 305-6387
    28 Liberty St.
    39th Fl.
    New York, NY 10005
    USA
UsernamePublicRestriction

Register